Patent intelligence · US
US 6683096
Indolylpiperidine derivatives as antihistaminic and antiallergic agents
Indolylpiperidine derivatives as antihistaminic and antiallergic agents
Patent details — US 6683096
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jan 27, 2004
- Expiration
- Jan 22, 2024
- Applicant
- Almirall Prodesfarma S.A.
- Claims
- 16
- CPC classes
- A61P, A61P11/00, A61P11/02, A61P11/04
Quick answer
US 6683096 (Indolylpiperidine derivatives as antihistaminic and antiallergic agents) is held by Almirall Prodesfarma S.A.. Status: expired. Granted Jan 27, 2004. Expires Jan 22, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Almirall Prodesfarma S.A.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61P, A61P11/00, A61P11/02, A61P11/04, A61P11/06, A61P17/00
More from Almirall Prodesfarma S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 6683096?
US 6683096 (Indolylpiperidine derivatives as antihistaminic and antiallergic agents) is held by Almirall Prodesfarma S.A.. Status: expired. Granted Jan 27, 2004. Expires Jan 22, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6683096?
Almirall Prodesfarma S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 6683096 expire?
Our index shows an expiration date of Jan 22, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.